PMID- 12435046
OWN - NLM
STAT- MEDLINE
DCOM- 20030501
LR  - 20051116
IS  - 1464-8431 (Print)
IS  - 1464-8431 (Linking)
VI  - 4
IP  - 5
DP  - 2002 Oct
TI  - Dendritic cell vaccines for cancer treatment.
PG  - 452-8
AB  - The success of cancer immunotherapy depends on two major factors: adequate 
      tumor-specific antigens and a vehicle capable of inducing a tumor-specific immune 
      response by effective delivery of these antigens. Dendritic cells (DCs) are the 
      most powerful antigen presenting cells, and because of their unique 
      characteristics, these cells are actively used in cancer immunotherapy. In this 
      review we describe recent data regarding different methods of loading these cells 
      with tumor-associated antigens, including RNA or DNA transfer. We will discuss 
      requirements for DC activation as pre-requisite for the success of cancer 
      immunotherapy.
FAU - Gabrilovich, Dmitry I
AU  - Gabrilovich DI
AD  - H Lee Moffitt Cancer Center, University of South Florida, Tampa 33612, USA. 
      GabrilDI@moffitt.usf.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Mol Ther
JT  - Current opinion in molecular therapeutics
JID - 100891485
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Neoplasms/*therapy
RF  - 36
EDAT- 2002/11/19 04:00
MHDA- 2003/05/02 05:00
CRDT- 2002/11/19 04:00
PHST- 2002/11/19 04:00 [pubmed]
PHST- 2003/05/02 05:00 [medline]
PHST- 2002/11/19 04:00 [entrez]
PST - ppublish
SO  - Curr Opin Mol Ther. 2002 Oct;4(5):452-8.